[go: up one dir, main page]

BR0313120A - bleb and de los preparations, neisserial / neisserial strain (s), immunogenic composition or vaccine, and, manufacturing processes of the neisserial bleb preparation vaccine and production of a bleb preparation - Google Patents

bleb and de los preparations, neisserial / neisserial strain (s), immunogenic composition or vaccine, and, manufacturing processes of the neisserial bleb preparation vaccine and production of a bleb preparation

Info

Publication number
BR0313120A
BR0313120A BRPI0313120-3A BR0313120A BR0313120A BR 0313120 A BR0313120 A BR 0313120A BR 0313120 A BR0313120 A BR 0313120A BR 0313120 A BR0313120 A BR 0313120A
Authority
BR
Brazil
Prior art keywords
bleb
neisserial
vaccine
los
preparation
Prior art date
Application number
BRPI0313120-3A
Other languages
Portuguese (pt)
Inventor
Ralph Biemans
Philippe Denoel
Christiane Feron
Carine Goraj
Jan Poolman
Vincent Weynants
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0218051A external-priority patent/GB0218051D0/en
Priority claimed from GB0218037A external-priority patent/GB0218037D0/en
Priority claimed from GB0218035A external-priority patent/GB0218035D0/en
Priority claimed from GB0218036A external-priority patent/GB0218036D0/en
Priority claimed from GBGB0220199.4A external-priority patent/GB0220199D0/en
Priority claimed from GBGB0220197.8A external-priority patent/GB0220197D0/en
Priority claimed from GB0225531A external-priority patent/GB0225531D0/en
Priority claimed from GB0225524A external-priority patent/GB0225524D0/en
Priority claimed from GB0230164A external-priority patent/GB0230164D0/en
Priority claimed from GB0230168A external-priority patent/GB0230168D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Priority claimed from PCT/EP2003/008568 external-priority patent/WO2004014417A2/en
Publication of BR0313120A publication Critical patent/BR0313120A/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

PREPARAçõES DE BLEB E DE LOS, CEPA(S) NEISSERIAL/NEISSERIAIS, COMPOSIçãO IMUNOGêNICA OU VACINA, E, PROCESSOS DE FABRICAçãO DA VACINA DE PREPARAçãO DE BLEB NEISSERIAL E DE PRODUçãO DE UMA PREPARAçãO DE BLEB. A presente invenção refere-se ao campo das composições de vacina neisseriais, a sua fabricação, e ao uso de referidas composições na medicina. Mais particularmente, ela refere-se a processos para a preparação de cepas meningocócicas que são vantajosas para a produção de vacinas de vesícula de membrana externa (ou bleb) neisseriais, em particular meningocócicas. Descreve-se também processos e produtos de vacina vantajosos com base no uso de vacinas inéditas de vesícula de membrana externa (ou bleb) meningocócicas ou de subunidade de LOS que foram tornadas mais seguras e/ou mais efetivas para uso em sujeitos humanos. Em particular, descreve-se combinações de regulações para baixo de genes, como PorA <sym> OpA, PorA e OpC, OpA e OpC, e PorA e OpA e OpC. Alternativamente, ou adicionalmente, mostra-se que lgtB<sym> é uma mutação ótima para se utilizar de maneira efetiva e segura L3 e/ou L2 de LOS em composições de vacina de Neisseria. Descreve-se adicionalmente vacinas de bleb derivadas de mutantes meningocócicos com deficiência de polissacarídeo capsular e lgtB<sym>; e também processos vantajosos para fabricar preparações de bleb em que se pretende conservar LOS como um antígeno importante.PREPARATIONS OF BLEB AND LOS, NEISSERIAL / NEISSERIAL CUP (S), IMMUNOGENIC COMPOSITION OR VACCINE, AND PROCESSES FOR MANUFACTURING THE NEISSERIAL BLEB PREPARATION AND PRODUCTION OF A BLEB PREPARATION. The present invention relates to the field of neisserial vaccine compositions, their manufacture, and the use of said compositions in medicine. More particularly, it relates to processes for the preparation of meningococcal strains that are advantageous for the production of neisserial outer membrane (or bleb), particularly meningococcal, bladder vaccines. Advantageous vaccine processes and products based on the use of unprecedented meningococcal outer membrane bleb (or bleb) or LOS subunit vaccines that have been made safer and / or more effective for use in human subjects. In particular, combinations of down-regulation of genes such as PorA <sym> OpA, PorA and OpC, OpA and OpC, and PorA and OpA and OpC are described. Alternatively, or in addition, lgtB <sym> is shown to be an optimal mutation for effectively and safely using LOS and / or L2 LOS in Neisseria vaccine compositions. Bleb vaccines derived from meningococcal mutants with capsular polysaccharide deficiency and lgtB <sym> are further described; and also advantageous processes for making bleb preparations in which LOS is to be preserved as an important antigen.

BRPI0313120-3A 2002-08-02 2003-07-31 bleb and de los preparations, neisserial / neisserial strain (s), immunogenic composition or vaccine, and, manufacturing processes of the neisserial bleb preparation vaccine and production of a bleb preparation BR0313120A (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
GB0218035A GB0218035D0 (en) 2002-08-02 2002-08-02 Vaccine composition
GB0218036A GB0218036D0 (en) 2002-08-02 2002-08-02 Vaccine
GB0218051A GB0218051D0 (en) 2002-08-02 2002-08-02 Vaccine composition
GB0218037A GB0218037D0 (en) 2002-08-02 2002-08-02 Vaccine composition
GBGB0220199.4A GB0220199D0 (en) 2002-08-30 2002-08-30 Mutant protein and refolding method
GBGB0220197.8A GB0220197D0 (en) 2002-08-30 2002-08-30 Refolding method
GB0225531A GB0225531D0 (en) 2002-11-01 2002-11-01 Vaccine
GB0225524A GB0225524D0 (en) 2002-11-01 2002-11-01 Vaccine composition
GB0230164A GB0230164D0 (en) 2002-12-24 2002-12-24 Vaccine composition
GB0230168A GB0230168D0 (en) 2002-12-24 2002-12-24 Vaccine composition
PCT/EP2003/008568 WO2004014417A2 (en) 2002-08-02 2003-07-31 Vaccine compositions comprising l2 and/or l3 immunotype lipooligosaccharides from lgtb- neisseria minigitidis

Publications (1)

Publication Number Publication Date
BR0313120A true BR0313120A (en) 2007-07-17

Family

ID=34705473

Family Applications (2)

Application Number Title Priority Date Filing Date
BR0313100-9A BR0313100A (en) 2002-08-02 2003-07-31 Immunogenic composition, isolated immunogenic composition, vaccine, method of treating or preventing gram-negative bacterial disease, use of the vaccine, genetically engineered gram-negative bacterial strain, method of preparing the immunogenic composition, method of preparing the vaccine, method of preparing a immunoglobulin for use in the prevention or treatment of neisserial infection, immunoglobulin preparation, pharmaceutical preparation, and use of pharmaceutical preparation
BRPI0313120-3A BR0313120A (en) 2002-08-02 2003-07-31 bleb and de los preparations, neisserial / neisserial strain (s), immunogenic composition or vaccine, and, manufacturing processes of the neisserial bleb preparation vaccine and production of a bleb preparation

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR0313100-9A BR0313100A (en) 2002-08-02 2003-07-31 Immunogenic composition, isolated immunogenic composition, vaccine, method of treating or preventing gram-negative bacterial disease, use of the vaccine, genetically engineered gram-negative bacterial strain, method of preparing the immunogenic composition, method of preparing the vaccine, method of preparing a immunoglobulin for use in the prevention or treatment of neisserial infection, immunoglobulin preparation, pharmaceutical preparation, and use of pharmaceutical preparation

Country Status (2)

Country Link
CN (1) CN103007263A (en)
BR (2) BR0313100A (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107722120B (en) * 2017-08-29 2020-07-14 杭州医学院 A kind of serum for treating otitis media caused by Haemophilus influenzae and application of the serum
CN107602697B (en) * 2017-08-29 2020-05-05 杭州医学院 Serum for treating nasosinusitis caused by haemophilus influenzae and application of serum

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9726398D0 (en) * 1997-12-12 1998-02-11 Isis Innovation Polypeptide and coding sequences
EP2270174A1 (en) * 1999-05-19 2011-01-05 Novartis Vaccines and Diagnostics S.r.l. Combination neisserial compositions
GB9918319D0 (en) * 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition

Also Published As

Publication number Publication date
CN103007263A (en) 2013-04-03
BR0313100A (en) 2005-06-21

Similar Documents

Publication Publication Date Title
MY149591A (en) Vaccines comprising l2 and/or l3 los from neisseria
BR112012022688A2 (en) fusion protein, isolated outer membrane vesicle, polynucleotide, pharmaceutical composition, vaccine, method for treating or preventing neisseria infection or disease, use and method for making a fusion protein
BR0107972A (en) Use of a hiv tat, hiv nef, or hiv tat protein or polynucleotide attached to a hiv nef protein or polynucleotide (nef-tat), and a hiv gp120 protein or polynucleotide, method for immunizing a hiv human being against hiv, and vaccine composition for human use
BRPI0409459A (en) New Immunogenic Compositions for the Prevention and Treatment of Meningococcal Disease
BRPI0210010B8 (en) peptide immunogen, as well as composition and application comprising them
BR0015961A (en) 85kda neisserial antigen
AU1568400A (en) Intervertebral disc prosthesis
AR041880A1 (en) IMMUNOGEN COMPOSITION
BR0212999A (en) New Immunogenic Compositions for the Prevention and Treatment of Meningococcal Disease
BR0311777A (en) Multivalent meningococcal vesicle composition, vaccine for treatment of neisserial disease, methods for manufacturing multivalent meningococcal vesicle composition and for prevention or treatment of neisserial disease, and use of an immunologically effective amount of the vaccine
ZA200602246B (en) Immunogenic HIV compositions and related methods
BR0313120A (en) bleb and de los preparations, neisserial / neisserial strain (s), immunogenic composition or vaccine, and, manufacturing processes of the neisserial bleb preparation vaccine and production of a bleb preparation
JP2019520090A (en) Vaccine composition comprising attenuated mutant Zika virus
BRPI0606165A2 (en) method of inducing a memory t-cell immune response against at least one antigen in a human patient, use of an immunogenic composition comprising a non-replicating or replication-matched virulent infection virus vector expressing the translation product of a mycobacterial ag85a gene, use of an antigen in the manufacture of a medicament for treating a disease in a patient by inducing a central memory t-cell immune response and vector vaccine
CN105560586B (en) Composition for artificial tear gel and artificial tear gel prepared therefrom
Van Den Dobbelsteen et al. From HexaMen to NonaMen: expanding a multivalent PorA-based meningococcal outer membrane vesicle vaccine
WO2021144478A3 (en) Combination treatment for fumarate-related diseases
CA2295316A1 (en) Homogeneous human papilloma virus capsomere containing compositions, methods for manufacture, and the use thereof as diagnostic, prophylactic or therapy
Harboe Armauer Hansen-the man and his work
CL2023001142A1 (en) Compositions and methods for vaccination against Neisseria gonorrhoeae
BRPI0415519A (en) method for increasing cd8 + cytotoxic t cell responses and for treating multiple sclerosis
Nakhat et al. Design and Evaluation of Silymarin-HP HP--ß-CD Solid Dispersion Tablets.
Turkova et al. Weight gain in children and adolescents on dolutegravir vs standard of care in the ODYSSEY trial
MX2023009728A (en) Meningococcal b recombinant vaccine.
ES2401276B1 (en) USE OF A GENICAL AND / OR PEPTIDE CONSTRUCTION FOR THE MANUFACTURE OF A VACCINE FOR THE PREVENTION AND / OR TREATMENT OF THE INFECTION CAUSED BY THE VIRUS OF THE AFRICAN SWINE FEVER (VPPA).

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07F Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]